, /PRNewswire/ -- Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, launch a new assay for quantifying pharmacodynamic markers of radioligand therapies in tumors. The development of this assay was presented in a poster entitled "Quantifying pharmacodynamic markers of radioligand therapies (RLTs) in tumor by multiplex immunofluorescence and automated quantitative analysis (AQUA) algorithms" at the American Association for Cancer Research (AACR) 2024 Annual Meeting held in Navigate BioPharma Services' new image-based test measures the changes in the cancer cells and the tissue after RLT.
This innovative assay utilizes multiplex immunofluorescence (mIF) combined with automated quantitative analysis (AQUA) algorithms to precisely measure changes in key protein markers within tumor tissues following radioligand therapy. For example, ionizing radiation produced by radioisotopes linked to antibodies causes double stranded breaks either directly or via generation of reactive oxygen species. This type of DNA damage is associated with an increase in markers for cell cycle arrest (e.
g., p21/CIP1) and DNA repairing proteins (e.g.
, CHK2 and gH2Ax). Additionally, proliferating cells (identifiable by Ki67) are most susceptible to ionizing radiation as DNA is exposed during mitotic phase of cell cycle. These biologically verified markers are incorporat.
